Cellular cardiomyoplasty

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Death rates due to heart failure continue to rise steadily in the western world despite better strategies designed to salvage damaged or dying myocardium after myocardial infarction.[1] In the United States alone, it is estimated that 5 million people have congestive heart failure presently and 500,000 more are diagnosed each year.[2] The most prominent cause of myocardial infarction (MI) and subsequent myocardial cell death is undiagnosed coronary artery disease resulting in plaque rupture or dislodgement and myocardial cell ischemia. After an MI, myocardial cells that die or are damaged are replaced by collagen and fibroblasts in a healing process that remodels the heart, most typically the left ventricle. This tissue is non-functioning scar tissue and often leads to a permanent decrease in the efficiency of the myocardium.[3][4]

Cellular cardiomyoplasty, or cell-based cardiac repair, is a new potential therapeutic modality in which progenitor cells are used to repair regions of damaged or necrotic myocardium. The ability of transplanted progenitor cells to improve function within the failing heart has been shown in experimental animal models and in some human clinical trials.[5] In November 2011, a large group of collaborators at Minneapolis Heart Institute Foundation at Abbott Northwestern found no significant difference in left ventricular ejection fraction (LVEF) or other markers, between a group of patients treated with cellular cardiomyoplasty and a group of control patients.[6] In this study, all patients were post MI, post percutaneous coronary intervention (PCI) and that infusion of progenitor cells occurred 2–3 weeks after intervention. In a study that is currently underway (February 2012), however, more positive results were being reported: In the SCIPIO trial, patients treated with autologous cardiac stem cells post MI have been reported to be showing statistically significant increases in LVEF and reduction in infarct size over the control group at four months after implant. Positive results at the one-year mark are even more pronounced.[7] Yet the SCIPIO trial "was recently called into question".[8][9] Harvard University is "now investigating the integrity of some of the data".[10] The Lancet recently published an non-specific ‘Expression of concern’ about the paper.[11] Subsequently another preclinical study also raised doubts on the rational behind using this special kind of cells,[12] as it was found that the special cells only have a minimal ability in generating new cardiomyocytes.[13] Some specialists therefore now raise concerns to continue.[14]

Progenitor cell lines[edit]

To date, the ideal progenitor cells have not been found or created. With the goal of recreating human tissue, the use of embryonic stem cells (ESC) was the initial logical choice. These pluripotent cells can conceptually give rise to any somatic cell line in the human body and while animal studies have shown restoration of cardiac function, immunologic rejection issues and teratoma formation have rendered ESC's a high risk.[15][16]

Human-induced pluripotent stem cells (iPSCs) are a cell line derived from somatic cells which have been induced through a combination of transcription factors. The iPSC line is very similar or identical to ESCs in many regards and also shows great promise in cardiac potential.[17] This cell line, however, is also less than ideal in that this cell type has been unable to mature into a homogeneous cell culture, making it immunogenic and teratogenic.[18] To date, neither of the above cell lines has been involved in a clinical trial for the issues mentioned.

A third cell line that shows great promise and has no known safety concerns is the adult stem cell derived from bone marrow or from cardiac tissue explants. It has been shown in several studies that adult stem cells do have cardiogenic potential.[19][20][21] Additionally, adult stem cells derived from bone marrow and cardiac harvest are safe and have never been implicated in immune or oncogenic episodes. The downsides to utilizing adult stem cells are limited proliferation, low quantities, low survival, low persistence and commitment. The bottom line is that these cells have been stressed and aged unlike ESCs and iPSCs but the upside is the lack of all deleterious effects of the younger cell lines. Progenitor cells derived from cardiac tissue explants are being utilized in the SCIPIO trial discussed in the "Overview" section (ClinicalTrials.gov identifier NCT00474461).

Future direction[edit]

Presently, the success of adult stem cells in regenerating human myocardium is just a fraction of what it could be. Three major challenges have been observed. Adult stem cells exhibit a minimal[clarification needed] commitment to engraft into the damaged myocardium, they have low survival rates and they have limited proliferation.[22] The positive effects observed in clinical trials today are a result of the work of donated stem cells that persist in the damaged myocardium for just days to weeks after delivery. Clearly, if cell survival is prolonged, these effects could be greatly enhanced.[citation needed] This is where a majority of research is being done today and several methodologies hold great promise.[23][24]

It has been shown that survival rates can be extended by conditioning stem cells with pre-treatments such as cytokines, growth factors, anti-aging compounds and exposure to hypoxic (low oxygen) conditions prior to delivery into host tissue.[25][26] Genetic modifications which lend endurance and longevity to stem cells placed in damaged myocardium are being investigated as well. Modification by integrated or episomal DNA has been shown to potentiate longevity in stem cells with such factors as GSK3-β, GATA4, Bcl-2, and HSP-20.[27]

Adult stem cell commitment is required for the production of new myocytes, blood vessels and endothelium after donation. While there are methods to induce cellular differentiation utilized with success in other tissue, there has been limited success with myocardial tissue. One of the most promising new techniques has to do with manipulating cells with Notch, a network regulator of commitment and survival that has been very effective in myocardial tissue.[28] There is more work to be done but it seems likely that Notch may be an effective enhancer of stem cell commitment and longevity.[citation needed]

As the field of regenerative medicine grows during its second decade of intense research, there is an international quest for greater understanding. Much is being learned quickly and it will only be a matter of time before new successes lead to real clinical advances in the growing patient population with myocardial compromise.[citation needed]

References[edit]

  1. ^ Forte, E.; Chimente (Nov 2011). "Cardiac cell therapy: the next (re)generation". Sterm Cell Rev. 7 (4): 1018–1030. doi:10.1007/s12015-011-9252-8. PMID 21437575. 
  2. ^ Hunt, Sharon; Abraham (Sep 2005). "ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult". Journal of the American College of Cardiology and Circulation. Retrieved 5 February 2012. 
  3. ^ Beltrami, AP; Urbanek (June 2001). "Evidence that human cardiac myocytes divide after myocardial infarction.". N Engl J Med 344 (23): 1750–1757. doi:10.1056/NEJM200106073442303. PMID 11396441. 
  4. ^ Anversa, Piero; Kajstura (1998). "Ventricular Myocytes Are Not Terminally Differentiated in the Adult Mammalian Heart". Circulation Research (83): 1–14. doi:10.1161/01.RES.83.1.1. Retrieved 5 February 2012. 
  5. ^ Murry CE (2005). "Cell-Based Cardiac Repair: Reflections at the 10-Year Point". Circulation 112 (20): 3174–83. doi:10.1161/CIRCULATIONAHA.105.546218. 
  6. ^ Traverse, JH; Ellis (Nov 2011). "Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.". JAMA 306 (19): 2110–9. doi:10.1001/jama.2011.1670. PMID 22084195. 
  7. ^ Bolli, R; Chugh (Nov 2011). "Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial.". Lancet 378 (9806): 1847–57. doi:10.1016/S0140-6736(11)61590-0. PMID 22088800. 
  8. ^ Abbott, A (May 2014). "Doubts over heart stem-cell therapy.". Nature 509 (7498): 15–16. doi:10.1038/509015. PMID 24784193. 
  9. ^ http://www.forbes.com/sites/larryhusten/2014/04/11/lancet-editors-raises-more-questions-about-prominent-harvard-stem-cell-researcher/
  10. ^ Abbott, A (May 2014). "Doubts over heart stem-cell therapy.". Nature 509 (7498): 15–16. doi:10.1038/509015. PMID 24784193. 
  11. ^ The Lancet editors (April 2014). "Expression of concern: the SCIPIO trial.". Lancet 383 (9925): 1279. doi:10.1016/S0140-6736(14)60608-5. 
  12. ^ van Berlo, J; et al. "c-kit+ cells minimally contribute cardiomyocytes to the heart.". Nature 509: 337–341. doi:10.1038/nature13309. 
  13. ^ http://www.tctmd.com/show.aspx?id=124193
  14. ^ http://www.tctmd.com/show.aspx?id=124193
  15. ^ Yang, L; Adler (May 2008). "Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population.". Nature 453 (7194): 524–528. doi:10.1038/nature06894. PMID 18432194. 
  16. ^ Asano, T; Sasaki (2006). "In vivo tumor formation from primate embryonic stem cells.". Methods of Molecular Biology 329: 459–467. doi:10.1385/1-59745-037-5:459. PMID 16846010. 
  17. ^ Shiba, Y; Laflamme (2009). "Cardiac applications for human pluripotent stem cells.". Current Pharmaceutical Design 15 (24): 2791–806. doi:10.2174/138161209788923804. PMC 2901183. PMID 19689350. Retrieved 21 March 2012. 
  18. ^ Wu, SM; Hochedlinger, K., (June 2011). "Harnessing the potential of induced pluripotent stem cells for regenerative medicine.". Nature Cell Biology 13 (6): 734. doi:10.1038/ncb0511-497. PMID 21540845. 
  19. ^ Beltrami, AP; Barlucchi,L.; Torella,D.; Baker,M.; Limana,F. et al. (September 2003). "Adult cardiac stem cells are multipotent and support myocardial regeneration.". Cell 114 (6): 763–776. doi:10.1016/S0092-8674(03)00687-1. PMID 14505575. 
  20. ^ Smits, AM; van Vliet P; et al. (2009). "Human cardiomyocyte progenitor cells differentiate into functional mature cardiomyocytes: an in vitro model for studying human cardiac physiology and pathophysiology.". Nature Protocols 4 (2): 232–243. doi:10.1038/nprot.2008.229. PMID 19197267. 
  21. ^ Fischer, KM; Cottage CT; Wu W; Din S; Gude NA; Avitabil D; Quijada P; Collins BL; Fransioli J; Sussman MA (Nov 2009). "Enhancement of myocardial regeneration through genetic engineering of cardiac progenitor cells expressing Pim-1 kinase.". Circulation 120 (21): 2077–2087. doi:10.1161/CIRCULATIONAHA.109.884403. PMC 2787902. PMID 19901187. Retrieved 21 March 2012. 
  22. ^ Mohsin, Sadia; Siddiqu S; Collins B; Sussman M (December 2011). "Empowering adult stem cells for myocardial regeneration.". Circulation Research 109 (12): 1415–1428. doi:10.1161/CIRCRESAHA.111.243071. PMID 22158649. 
  23. ^ Pagani, FD; DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, Aaronson KD (March 2003), "Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation.", J Am Coll Cardiol 41: 879–888, PMID 12628737 
  24. ^ Muller-Ehmsen, J; Whittaker P; Kloner RA; Dow JS; Sakoda T; Long TI; Laird PW; Kedes L. (Feb 2002). "Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium.". J Mol Cell Cardiol. 34: 107–116. doi:10.1006/jmcc.2001.1491. PMID 11851351. 
  25. ^ Niagara, MI; Haider H; Jiang S; Ashraf M. (March 2007). "Pharmacologically pre-conditioned skeletal myoblasts are more resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart.". Circulation Research 100 (4): 545–555. doi:10.1161/01.RES.0000258460.41160.ef. PMID 17234963. 
  26. ^ Rosová, L; Dao M; Capoccia B; Link D; Nolta JA. (Aug 2008). "Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells.". Stem Cells 26 (8): 2173–82. doi:10.1634/stemcells.2007-1104. PMC 3017477. PMID 18511601. 
  27. ^ Mohsin, S; Siddiqi, S, Collins B, Sussman Mark (Dec 2011). "Empowering adult stem cells for myocardial regeneration". Circulation Research 109 (12): 1415–28. doi:10.1161/CIRCRESAHA.111.243071. PMID 22158649. 
  28. ^ Boni, A; Urbanek K; Nascimbene A; Hosoda T; et al (Oct 2008). "Notch 1 regulates the fate of cardiac progenitor cells". Proc Natl Acad Sci U S A. 105 (40): 15529–34. doi:10.1073/pnas.0808357105. PMC 2563067. PMID 18832173. Retrieved 31 March 2012.